HR 5668
116th Congress
House
Health
Congressional oversight
Drug safety, medical device, and laboratory regulation
Prescription drugs
MODERN Labeling Act of 2020
Introduced: January 24, 2020
Introduced by:
Matsui, Doris O.
Democratic
· California
See on congress.gov
Everywhere this bill has been
16 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Nov 18, 2020
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Nov 17, 2020
Motion to reconsider laid on the table Agreed to without objection.
Nov 17, 2020
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5805-5806)
Nov 17, 2020
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5805-5806)
Nov 17, 2020
DEBATE - The House proceeded with forty minutes of debate on H.R. 5668.
Nov 17, 2020
Considered under suspension of the rules. (consideration: CR H5805-5807)
Nov 17, 2020
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Nov 16, 2020
Placed on the Union Calendar, Calendar No. 471.
Nov 16, 2020
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-573.
Jul 15, 2020
Ordered to be Reported (Amended) by Voice Vote.
Jul 15, 2020
Committee Consideration and Mark-up Session Held.
Mar 11, 2020
Subcommittee Consideration and Mark-up Session Held.
Mar 11, 2020
Ordered to be Reported (Amended) by Voice Vote.
Jan 25, 2020
Referred to the Subcommittee on Health.
Jan 24, 2020
Referred to the House Committee on Energy and Commerce.
Jan 24, 2020
Introduced in House
Plain-English summary
Making Objective Drug Evidence Revisions for New Labeling Act of 2020 or the MODERN Labeling Act of 2020
This bill authorizes the Food and Drug Administration (FDA) to require updates to outdated labels for certain generic drugs if the updates will provide a public health benefit. Generally, the FDA may use this authority to update the label of a generic version of a brand-name drug that has been withdrawn from the market for reasons other than safety or effectiveness.
What's happening now
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Committees of jurisdiction
3
Cosponsors
1